SB 241 (see companion bill HB 2529) – Texas
Status: EnactedYear Introduced: 2023
Link: https://capitol.texas.gov/BillLookup/History.aspx?LegSess=88R&Bill=SB241
Relating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability.
Return to Database Search
© 2018- The SLIHCQ Database. Initial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.
Associated Litigation:
No items found